These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17763220)

  • 1. Implications of circulating chromogranin A in prostate cancer.
    Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
    Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
    Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
    Custovic Z; Kraus O; Tomaskovic I; Tarle M
    Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
    Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
    Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
    Chuang CK; Wu TL; Tsao KC; Liao SK
    J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between age and Chromogranin A determination in prostate diseases.
    Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M
    Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
    Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
    Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
    Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
    Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
    Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
    Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.